Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma
Abstract
Histamine dihydrochloride is a vasoactive biogenic amine. It inhibits the reactive oxygen species formation in monocytes via histamine H2 receptors and protects natural killer and T cells from oxidative damage. Histamine has the potential to optimize cytokine-induced activation of T cells and natural killer cells; therefore, the addition of histamine to cytokine treatment may improve treatment efficacy. Clinical trials in solid tumors and in acute myeloid leukemia have demonstrated the potential to improve treatment outcome when histamine dihydrochloride is combined with immunotherapy. In patients with metastatic malignant melanoma, this strategy improved remission rates and increased survival. On the other hand, less promising results were reported for histamine dihydrochloride added to cytokines in patients with other solid tumors, especially in advanced renal cell carcinoma. A recent international Phase III trial performed in 320 patients showed that maintenance therapy with histamine dihydrochloride and IL-2 was able to improve leukemia-free survival in patients with acute myeloid leukemia, without an effect on overall survival. The combination of histamine dihydrochloride with IL-2 potentially offers an efficacious and tolerable maintenance strategy for patients with acute myeloid leukemia; however, its impact on survival remains to be explored.
Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
Bibliography
- 1 Hellstrand K, Hermodsson S: Synergistic NK cell activation by histamine and interleukin-2. Int. Arch. Allergy Appl. Immunol.92,379–389 (1990).Crossref, Medline, CAS, Google Scholar
- 2 Hellstrand K, Asea A, Dahlgren C, Hermodsson S: Histaminergic regulation of NK-cells: role of monocyte-derived, reactive oxygen metabolites. J. Immunol.153,4940–4947 (1994).• Details the mechanism of action of histamine.Medline, CAS, Google Scholar
- 3 Hellstrand K, Naredi P, Lindner P et al.: Histamine in immunotherapy of advanced melanoma. A pilot study. Cancer Immunol. Immunother.39,416–419 (1994).• Clinical trial in malignant melanoma.Crossref, Medline, CAS, Google Scholar
- 4 Hellstrand K, Asea A, Hermodsson S: Role of histamine in natural killer cell-mediated resistance against tumor cells. J. Immunol.145,4365–4370 (1990).• Details the mechanism of action of histamine.Medline, CAS, Google Scholar
- 5 Johansson S, Landstrom M, Hellstrand K, Henriksson R: The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation. Br. J. Cancer77,1213–1219 (1998).Crossref, Medline, CAS, Google Scholar
- 6 Wotherspoon HA, Anderson JR, Morran CG, Murray GD, McArdle CS: Randomised controlled trial of an H2-receptor antagonist in gastric cancer. Br. J. Surg.84,1168–1169 (1997).Crossref, Medline, CAS, Google Scholar
- 7 Lynch NR, Salomon JC: Passive local anaphylaxis: demonstration of antitumour activity and complementation of intratumour BCG. J. Natl Cancer Inst.58,1093–1098 (1977).Crossref, Medline, CAS, Google Scholar
- 8 Tatsuta M, Iishi H, Ichii M, Noguchi S, Yamamura H, Taniguchi H: Inhibitory effects of tetragastrin and histamine on carcinogenesis in the small intestines of W rats by N-methy-N´-nitro-N-nitrosoguanidine. J. Natl Cancer Inst.76,277–281 (1986).Medline, CAS, Google Scholar
- 9 Suonio E, Tuornisto L, Alhava E: Effects of histamine, H1, H2, Hic receptor antagonists and α-fluoromethyhistidine on the growth of human colorectal cancer in the subrenal capsule assay. Agents Actions41,118–120 (1994).Crossref, Medline, Google Scholar
- 10 Brunda MJ, Bellantoni D, Sulich V: In vivo anti-tumour activity of combinations of INF-α and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int. J. Cancer40,365–441 (1987).Crossref, Medline, CAS, Google Scholar
- 11 Brune M, Hansson M, Mellqvist UH, Hermodsson S, Hellstrand K: NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur. J. Haematol.57,312–319 (1996).• Details the mechanism of action of histamine.Crossref, Medline, CAS, Google Scholar
- 12 Hellstrand K, Mellqvist UH, Wallhult E et al.: Histamine and interleukin-2 in acute myelogenous leukemia. Leuk. Lymphoma27,429–438 (1997).Crossref, Medline, CAS, Google Scholar
- 13 Middleton M, Sarno M, Agarwala SS et al.: Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2. J. Clin. Pharmacol.42,774–781 (2002).Crossref, Medline, CAS, Google Scholar
- 14 Donskov F, Middleton M, Fode K et al.: Two randomised Phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma. Br. J. Cancer93,757–762 (2005).•• Details of clinical trials in renal cell carcinoma.Crossref, Medline, CAS, Google Scholar
- 15 Donskov F, Hokland M, Marcussen N, Torp Madsen HH, von der Maase H: Monocytes and neutrophils as ‘bad guys’ for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma – results from a randomised Phase II trial. Br. J. Cancer94,218–226 (2006).•• Describes a clinical trial in renal cell carcinoma.Crossref, Medline, CAS, Google Scholar
- 16 Atkins MB, Lotze MT, Dutcher JP et al.: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17,2105–2116 (1999).•• Describes treatment results in metastatic melanoma.Crossref, Medline, CAS, Google Scholar
- 17 Hellstrand K, Hermodsson S, Brune M, Naredi P, Carneskog J, Mellqvist UH: Histamine in cancer immunotherapy. Scand. J. Clin. Lab. Invest.57,193–202 (1997).Crossref, Medline, CAS, Google Scholar
- 18 Keilholz U: Biochemotherapy of melanoma. Forum (Genova)13,158–165 (2003).Medline, Google Scholar
- 19 Agarwala SS, Glaspy J, O’Day SJ et al.: Results from a randomized Phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J. Clin. Oncol.20,125–133 (2002).•• Describes a clinical trial in metastatic melanoma.Crossref, Medline, CAS, Google Scholar
- 20 Asemissen AM, Scheibenbogen C, Letsch A et al.: Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomised clinical trial of interleukin 2 with or without histamine (MP 104). Clin. Cancer Res.11,290–297 (2005).Medline, CAS, Google Scholar
- 21 Brune M, Castaigne S, Catalano J et al.: Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomised Phase 3 trial. Blood108,88–96 (2006).•• Describes a clinical trial in acute myeloid leukemia.Crossref, Medline, CAS, Google Scholar
- 22 Galmarini CM: Histamine dihydrochloride (subcutaneous) Maxim. Curr. Opin. Investig. Drugs5,1298–1310 (2004).Medline, CAS, Google Scholar
